Fe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for in Vivo Imaging and Focused Photothermal Therapy

Pharmaceutics

Carlos Caro¹  Alejandro Domínguez¹  JoseMaría Páez-Muñoz¹  MariaLuisa García-Martín¹  JohnR. Pearson¹  AnaM. Beltrán²  Francisco Gámez³  ManuelPernía Leal⁴  JesúsM.De la Fuente⁵  Yilian Fernandez-Afonso⁵  Eulália Pereira⁶  Pedro Quaresma⁶  Ricardo Franco⁷ 

[1] BIONAND—Centro Andaluz de Nanomedicina y Biotecnología (Junta de Andalucía-Universidad de Málaga), C/ Severo Ochoa, 35, 29590 Málaga, Spain;Departamento de Ingeniería y Ciencia de los Materiales y del Transporte, Escuela Politécnica Superior, Universidad de Sevilla, Virgen de África 7, 41011 Sevilla, Spain;Departamento de Química Física, Universidad de Granada, Avenida de la Fuente Nueva S/N, 18071 Granada, Spain;Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, 41012 Seville, Spain;Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain;REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal;UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal;

关键词: imaging-guided therapy;    multimodal imaging;    contrast agent;    MRI;    CT;   

DOI  :  10.3390/pharmaceutics13030416

来源: DOAJ

【 摘 要 】

In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable “light-to-heat” conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against glioblastoma multiforme in a mouse model.

【 授权许可】

Unknown